Producer
Pfizer (Essential Health / Injectable Opioids)
3
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
3 inputs Pfizer (Essential Health / Injectable Opioids) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Pfizer (Essential Health / Injectable Opioids) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Primary Care and Specialty
45%COVID Products (Declining)
15%Hospital Products (Hospira legacy)
13%Oncology
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2015
Pfizer — publicly known for Lipitor, COVID vaccines, and Viagra — is simultaneously the dominant US supplier of hospital injectable opioids (60% market share via the largely invisible Hospira subsidiary, acquired for $17B in 2015), the global near-monopoly supplier of pneumococcal conjugate vaccines (Prevnar 13/20, protecting infants from bacterial meningitis), and the dominant supplier of hospital IV antibiotics (vancomycin, piperacillin/tazobactam). These three product lines — ICU pain management, childhood immunization, and sepsis treatment — are all manufactured in the same Pfizer/Hospira sterile fill-finish network. A single quality event or manufacturing disruption at a shared Pfizer facility cascades simultaneously across all three.
Pfizer Inc. ↗Capacity2018
Pfizer/Hospira's Rocky Mount, NC facility is the single largest sterile injectable manufacturing site in the United States by production volume, producing injectable opioids (morphine, hydromorphone, fentanyl), IV antibiotics (vancomycin, pip-tazo), and other hospital injectables on the same campus. A 2017 hurricane caused a temporary shutdown that immediately generated allocation constraints for multiple injectable drug categories across the US. ASHP declared multiple simultaneous drug shortages as a direct result of this single facility event — illustrating how the consolidation of hospital injectable manufacturing into one Pfizer campus created a systemic single point of failure for US hospital pharmacy.
American Society of Health-System Pharmacists ↗Origin2015
Pfizer's acquisition of Hospira in September 2015 for $17B was the largest pharmaceutical acquisition of that year and fundamentally changed Pfizer's supply chain footprint — adding 12 manufacturing facilities, 17,000 employees, and the position of dominant US hospital injectable supplier. Hospira had itself been spun off from Abbott Laboratories in 2004. The acquisition gave Pfizer control of the IV antibiotic, injectable opioid, and sterile IV fluid supply chains that underpin US hospital operations — businesses that produce ~$5-6B in annual revenue but are almost entirely invisible to the public who think of Pfizer as a branded drug company.
Pfizer Inc. ↗